N/A N=50 Randomized Treatment

Open Hemorrohoidectomy Vs Transanal Hemorrhoidal Desarterialization in Hemorrhoids Grade III: The Effect on Symptoms

Hemorrhoids Third Degree

Bottom Line

View on ClinicalTrials.gov: NCT06420986 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Mar 2026

Primary outcome: Primary: Hemorrhoidal Disease Symptom Score — 1; 7 units on a scale

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Open Hemorrhoidectomy (Procedure); Transanal Hemorrhoidal Dearterialization (Procedure)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Hospital Son Llatzer
Primary completion: Apr 2024

Outcome Measures

Outcome	Result	p-value
PRIMARY Hemorrhoidal Disease Symptom Score	1; 7	—
PRIMARY Short Health Scale in Hemorrhoidal Disease	7; 10	—
SECONDARY Postoperative Pain	5.58; 3.92	—
SECONDARY Fecal Incontinence	0; 0	—

Summary

The goal of this clinical trial is to learn if open hemorroidectomy diminishes symptoms compared to transanal hemorrhoidal desarterialization (THD) in patients presenting with hemorrhoids grade III. The main question it aims to answer is: - Do patients undergoing open hemorroidectomy present with lesser symptoms 1 year after surgery, compared to those undergoing a THD? Researchers will compare open hemorroidectomy to THD in terms of symptom response one year after the procedure. Participants will: * Undergo surgical treatment of hemorroids performed by one of the two techniques: open hemorroidectomy versus THD. * Fill in symptom forms before and one year after the surgical procedure. * Attend control visits one week, one month, three months and one year after the surgical procedure.

Eligibility Criteria

Inclusion criteria

Age older than 18.
Hemorroids grade III.
Surgical indication for hemorroid treatment.
Signed informed consent.

Exclusion criteria

Acute hemorroidal disease.
Previous hemorroidal surgery.
Concomitant anal fissure.
Concomitant perianal fistulae.
Concomitant rectal prolapse.
Inflamatory bowel disease.
Anal or colorrectal cancer.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT06420986). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.